<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01475032</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-0807-PR-0024</org_study_id>
    <secondary_id>2009-016757-18</secondary_id>
    <nct_id>NCT01475032</nct_id>
  </id_info>
  <brief_title>Efficacy Study of the Product &quot;CHF 1535&quot; Versus Beclomethasone (BDP) and Free Combo in Asthmatic Children</brief_title>
  <acronym>PAED2/FRESH</acronym>
  <official_title>A Phase III, 12-week, Multicentre, Multinational, Randomised, Double-blind, Double-dummy, 3 Arm-parallel Group Study to Test the Efficacy of CHF 1535 (Fixed Combination of Beclomethasone Dipropionate (BDP) Plus Formoterol Fumarate (FF)) Versus a Free Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate and Versus a Monotherapy of Beclomethasone Dipropionate in Partly Controlled Asthmatic Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that CHF 1535 in pressurized metered dose inhaler
      (pMDI) is non-inferior to the corresponding dose of free combination of Beclomethasone (BDP)
      and Formoterol Fumarate (FF) and superior to the corresponding dose of BDP in terms of lung
      functions in asthmatic children patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pre-dose FEV1 (forced expiratory volume in the first second)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessment of lung function parameter as pre-dose FEV1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient with Asthma symptoms</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patients with Asthma symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC (forced vital capacity)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessment of lung function parameter as FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue medication use</measure>
    <time_frame>12 weeks</time_frame>
    <description>rescue medication used by the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEF (peak expiratory flow)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessment of PEF as lung function parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>number of adverse event per patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood parameters</measure>
    <time_frame>at week 0 and week 12</time_frame>
    <description>Assessment of standard blood parameters (Hematology and chemistry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessment of heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessment of blood pressure</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">638</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>CHF 1535</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHF 1535 (BDP/FF) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BDP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BDP for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BDP+FF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>free combo BDP+FF for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 1535</intervention_name>
    <description>CHF 1535 (BDP/FF) for 12 weeks</description>
    <arm_group_label>CHF 1535</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beclomethasone (BDP)</intervention_name>
    <description>Beclomethasone (BDP) for 12 weeks</description>
    <arm_group_label>BDP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beclomethasone (BDP) + Formoterol Fumarate (FF)</intervention_name>
    <description>free combo Beclomethasone (BDP) + FF for 12 weeks</description>
    <arm_group_label>BDP+FF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female children (aged ≥ 5 and &lt; 12 years)

          -  Partly controlled asthma children according to Global Initiative for Asthma guidelines
             (GINA)

          -  Symptomatic asthmatic patients treated with BDP up to 400 micrograms or equivalent

          -  FEV1 ≥ 60% and ≤ 95% of predicted normal values

        Exclusion Criteria:

          -  Patients with two or more admissions to hospital for asthma exacerbation in the past
             12 months or any admission to intensive care ever.

          -  Occurrence of acute asthma exacerbations or lower respiratory tract infections in the
             4 weeks before study entry

          -  History of near fatal asthma

          -  History of cystic fibrosis, bronchiectasis or primary ciliary dyskinesia

          -  Diagnosis of restrictive lung disease.

          -  Patients treated with systemic corticosteroids

          -  Significant medical history and/or treatments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugenio BARALDI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Padova - Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMHAT &quot;Alexandrovska</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Necker Enfants Malades Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drez. Gelb &amp; Knecht</name>
      <address>
        <city>Bretten</city>
        <zip>75015</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Micro Care Kft</name>
      <address>
        <city>Szigetvár</city>
        <zip>7900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G.Gaslini Institute</name>
      <address>
        <city>Genoa</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytetu Medycznego</name>
      <address>
        <city>Łódź</city>
        <zip>22 90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Universitar de Urgenta Elias</name>
      <address>
        <city>Bucuresti</city>
        <zip>011461</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow State Medical University</name>
      <address>
        <city>Moscow</city>
        <zip>119435</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZZ- Detská pneumologická a ftizeologická ambulanci</name>
      <address>
        <city>Dolný Smokovec</city>
        <zip>059 81</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sabadell</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Pediatrics</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Ukraine</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016757-18</url>
    <description>Study Record on EU Clinical Trials Register including results</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2011</study_first_submitted>
  <study_first_submitted_qc>November 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2011</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>children</keyword>
  <keyword>chronic treatment</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

